Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + alzheimers + treatment  Related to the article below (Last Update: 8/4/2008)

New Alzheimer's treatment slows mental decline, study shows
Chicago Tribune, United States - Jul 29, 2008
By Jeremy Manier | Chicago Tribune reporter A new treatment for Alzheimer's disease significantly slowed elderly patients' mental decline and may have ...
New Alzheimer's Drug Could Be Effective, Cheap, and Unprofitable Wired News
New Alzheimer's drug is twice as effective as current treatments Telegraph.co.uk
New Alzheimer?s drug trial gives hope OnMedica
Xinhua - Sky News
all 630 news articles »

China Daily
Two New Alzheimer's Disease Studies Show Advances Against ...
FOXBusiness - Jul 29, 2008
"This also points to biological pathways in the brain, such as insulin signaling, that might be a focus for developing new treatment strategies. ...
CBS
Rates of Mild Cognitive Impairment Higher Than Expected U.S. News & World Report
Memory Pharmaceuticals Presents Positive Preclinical Data for MEM ... MarketWatch
Post-Bulletin - Reuters
all 263 news articles »  MEMY

Boston Globe
MS drug fear sends Elan shares crashing
Belfast Telegraph, United Kingdom -
Earlier this week Elan also reported disappointing results from its Alzheimer's treatment AAB-001, which resulted in a share slump. ...
Elan, Biogen Shares Plunge on New Tysabri Infections (Update3) Bloomberg
Risks Run High For Biogen, Elan Forbes
Elan Jumps into Recovery Mode Investerms.com
Irish Times - BioWorld Online
all 216 news articles »  ELN - BIIB - PINK:ELNCF

MedPage Today
Baxter boosted by drug's head start
Chicago Tribune, United States - Jul 31, 2008
Shares of Wyeth and Elan fell sharply Wednesday after their experimental Alzheimer's treatment known as bapineuzumab was linked to brain swelling in data ...
Cutting-Edge Alzheimer's Treatment ABC News
Baxter boosted by drug's head start: Alzheimer's candidate used ... Therapeutics Daily (subscription) (press release)
Dimebon Shines as Alzheimer's Therapy WebMD
MarketWatch - Bloomberg
all 85 news articles »  BAX - MDVN - OTC:CMTX
Alzheimer's Treatment Trials May Have Special Challenges
Washington Post, United States - Jul 28, 2008
MONDAY, July 28 (HealthDay News) -- It may be harder to prove the effectiveness of new Alzheimer's disease therapies, because researchers have been having a ...

ABC News
Alzheimer 'Breakthrough' Tempts Families to Improvise
ABC News - Jul 31, 2008
And a new potential treatment announced Tuesday may be no exception. Discussed at the annual Alzheimer's Association Meeting in Chicago, a drug called ...
Controversy About Lack of Placebo Group Decline in Alzheimer's ... Earthtimes (press release)
all 19 news articles »
Health Front and Center
Publishers Weekly, NY -
More than a century after German neuropathologist Alois Alzheimer first diagnosed a case of presenile dementia in 1901, there have been numerous attempts at ...

ChattahBox
Elan Tanks As Buzz For New Alzheimer's Drug Dies
Forbes, NY - Jul 30, 2008
But at a big Alzheimer's meeting in Chicago, there is little buzz in the air over Wyeth and Elan's new drug bapineuzumab. ...
Wyeth, Elan Fall on Doubts Raised by Alzheimer's Test (Update1) Bloomberg
A Second Chance to Buy Wyeth? Barron's
Intellect Neurosciences, Inc. Obtains Pivotal European Patent ... MarketWatch
nwitimes.com - Bloomberg
all 299 news articles »  ELN - PINK:ELNCF - OTC:ILNS

eFluxMedia
Scots Create Drug to Halt Alzheimer's Pill is 'Biggest ...
RedOrbit, TX -
Prof Wischik, who cofounded TauRx Therapeutics, which is developing the treatment, said: "This is an unprecedented result in the treatment of Alzheimer's. ...
Rember, the drug that helps alzheimers sufferers Times Online
Experimental Alzheimer's drug shows early promise Dallas Morning News
Alzheimer's brings heartache to millions but a breakthrough by a ... Scotsman
Chicago Tribune - Medscape (subscription)
all 49 news articles »

dBTechno
New drug boosts brain function in Alzheimer's patients
ABC Online, Australia - Jul 29, 2008
ASHLEY HALL: In the search for a treatment for Alzheimer's disease, researchers face the tough task of trying to find a drug that will both stop the disease ...
Study: Exercise slows Alzheimer's brain atrophy The Associated Press
Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show ... FOXBusiness
New drug aims to make Alzheimer's a distant memory WRAL.com
University of British Columbia - Nursing Times
all 678 news articles »
Source: Google News

… the efficacy and safety of ENA 713(rivastigmine tartrate), a new acetylcholinesterase inhibitor, in …
J Corey-Bloom, R Anand, J Veach - International Journal of Geriatric Psychopharmacology, 1998 - csa.com
... efficacy and safety of a new centrally acting ... rivastigmine tartrate), for patients
with Alzheimer's disease (AD ... were randomly assigned to treatment with placebo ...

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment -
RC Petersen, RG Thomas, M Grundman, D Bennett, R … - New England Journal of Medicine, 2005 - content.nejm.org
... AM J ALZHEIMERS DIS OTHER DEMEN 20: 295-302 [Abstract ... Mild Cognitive Impairment as
a Clinical Entity and Treatment Target ... What's new in the other general journals ...

Memantine in Moderate-to-Severe Alzheimer's Disease -
B Reisberg, R Doody, A Stoffler, F Schmitt, S … - New England Journal of Medicine, 2003 - content.nejm.org
... JWatch Psychiatry 2003: 7-7 [Full Text]; Rosack, J. (2003). New Drug Offers Hope
As Alzheimer's Treatment. Psychiatr. News 38: 1-55 [Full Text]; (2003). ...

Treatment of Alzheimer's disease: current status and new perspectives.
E Scarpini, P Scheltens, H Feldman - Lancet Neurol, 2003 - ncbi.nlm.nih.gov
Lancet Neurol. 2003 Sep;2(9):539-47. Click here to read Treatment of Alzheimer's
disease: current status and new perspectives. Scarpini ...

Treatment of Alzheimer's Disease -
R Mayeux, M Sano - New England Journal of Medicine, 1999 - content.nejm.org
... 2000). Treatment of Alzheimer's Disease. NEJM 342: 821-822 [Full Text];
(2000). New Treatments for Alzheimer's Disease Reviewed. ...

… pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of … -
RJ Polinsky - Clinical Therapeutics, 1998 - Elsevier
... Clinical Pharmacology of Rivastigmine: A New-Generation Acetylcholinesterase Inhibitor
for the Treatment of Alzheimer?s Disease Ronald J. Polinsky, MD ...

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase -
NH Greig, T Utsuki, QS Yu, X Zhu, HW Holloway, T … - Current Medical Research and Opinion, 2001 - ingentaconnect.com
... A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to
Butyrylcholinesterase. Authors: Greig NH; Utsuki T.; Yu QS ...

Alpha-lipoic acid as a new treatment option for Azheimer type dementia -
K Hager, A Marahrens, M Kenklies, P Riederer, G … - Archives of Gerontology and Geriatrics, 2001 - Elsevier
... A controlled trial of selegiline, alpha-tocopherol, or both as treatment for
Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl. J. Med. ...

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim … -
SL Rogers, LT Friedhoff - European Neuropsychopharmacology, 1998 - Elsevier
... has been reported for untreated Alzheimer's disease patients ... support the contention
that treatment benefits are ... aims in the development of new ChE inhibitors ...

Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease -
MW Jann - Pharmacotherapy, 2000 - PPI
R EVIEWS F T HERAPEUTICS _ Rivastigmine, a New-Generation Cholinesterase Inhibitor
for the Treatment of Alzheimer?s Disease Michael W. Jann, Pharm.D., FCCP ...

Source: Google Scholar
 
 

New Study Finds Treatment With Certain Anti-hypertensive Drugs May Reduce Alzheimer's Disease

Article Date: 12 Dec 2006 - 1:00am (PST)
A new cardiovascular drug screening has identified existing anti-hypertensive agents capable of preventing cognitive decline and amyloid neuropathology associated with Alzheimer's disease. The research, conducted by Dr. Gulio Maria Pasinetti at the Mount Sinai School of Medicine in New York, NY, was released at the American College of Neuropsychopharmacology's (ACNP) annual conference. These findings suggest that a large number of geriatric patients currently under pharmacological treatment for high-blood pressure with certain anti-hypertensive drugs may also reap the benefits of the drug's cognitive effects.

Dr. Pasinetti's research is part of a growing push to identify and develop more effective treatments for Alzheimer's disease. This devastating, degenerative illness is of particular concern now Boomers begin to turn 60 and are at increased risk for developing cognitive impairment and Alzheimer's disease.

"There is no convincing evidence that there is any available drug presently on the market to cure Alzheimer's disease, and there are many questions surrounding the effectiveness of drugs that are available to delay or effectively alleviate symptoms of memory deterioration or dementia," said Pasinetti.

Article continues below and (thank you)
 
Despite major breakthroughs over the past ten years in understanding the pathogenesis, molecular mechanisms and possible causes of Alzheimer's disease, limited progress has been done in the identification of novel therapeutic strategies that made a real impact in the prevention or treatment of the disease in the general population."

Over the past two years, researchers have begun screening drugs that are already commercially available for treatment of other disorders to determine their potential value in treating Alzheimer's disease and cognitive impairment.

Commonly prescribed drugs were administered in vitro to brain cells derived from animal models genetically predisposed to develop Alzheimer's disease amyloid neuropathology. The brain cells in vitro were then monitored to systematically assess the potential beneficial effect of novel drugs, especially in respect to generation of abnormally processed beta-amyloid.

Abnormally processed beta-amyloid has been identified as playing a key role in Alzheimer's disease pathogenesis, particularly in respect to cognitive deterioration.

Thus, characterization of novel drug treatments preventing abnormal beta-amyloid generation will help in the identification of future, novel pharmacological treatments for Alzheimer's disease.

Among several hundred drugs that were identified in Dr. Pasinetti's laboratory as having promise in preventing beta-amyloid build-up, seven of the drugs are commonly prescribed to treat hypertension. This recent, promising evidence indicates that cardiovascular anti-hypertensive agents may decrease the incidence or slow the progression of Alzheimer's disease.

During the course of the research, one drug in particular was identified as effective in blocking the accumulation of beta-amyloid in the brain and preventing the deterioration of cognitive performance. The drug, Propranololo-HCL (Inderal) for example, is widely prescribed in elderly patients to treat high blood pressure. Further research is necessary to determine if these patients may also be benefiting from the potential cognitive effects of the drug.

Pasinetti noted that it might also be possible to identify a concentration of this compound that confers the beta-amyloid blocking benefit without affecting blood pressure.

"If we can give this drug at concentrations that do not affect blood pressure, this drug could be made available for all members of the geriatric population identified as being at high risk for developing Alzheimer's disease," said Pasinetti.

Pasinetti was quick to point out the limitations of the research, noting that studies must be conducted in human subjects that examine the effects of the drug independent of its role as an anti-hypertensive agent.

"The use of these drugs for their potential anti-amyloidogenic role is still highly experimental, and at this stage we have no clinical data beyond phenomenological observation," said Pasinetti. "We need to complete clinical trials in the future if we are to identify preventive drugs, which will need to be prescribed at dosages that do not interfere with hypertension."

###

ACNP held its Annual Meeting December 3 - 7, 2006, in Hollywood, FL.

ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.

Contact: Sharon Reis
GYMR
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page